Status:

RECRUITING

The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.

Lead Sponsor:

Qing Su

Conditions:

Immunosenescence

Metabolism

Eligibility:

All Genders

50-70 years

Phase:

NA

Brief Summary

The ageing of our country is increasing and the ageing of the population has led to a significant increase in aging related diseases. During the aging process of the organism, cellular senescence can ...

Detailed Description

A randomised, placebo-controlled, parallel group study to assess the efficacy and safety of NMN in middle-aged and elderly people with immunosenescence. People aged 50-70 years will be included in the...

Eligibility Criteria

Inclusion

  • Age 50-70 years with overweight or obesity (BMI 24kg/m2);
  • At least one of the following three: metabolism-related fatty liver disease (diagnosed by ultrasound); pre-diabetes; type 2 diabetes mellitus with HbA1c \<7% without glucose-lowering drug therapy;
  • Agreed to participate in the trial and could adhere to the follow-up and visit the hospital on their own; signed the informed consent form.

Exclusion

  • Patients with tumours;
  • Patients with autoimmune diseases (excluding Hashimoto's thyroiditis);
  • Severe cardiovascular disease or cardiac insufficiency;
  • Systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg;
  • Chronic obstructive pulmonary disease;
  • Chronic active hepatitis or cirrhosis;
  • Chronic renal insufficiency;
  • Stroke patients
  • Severe haematological diseases;
  • Infectious diseases;
  • Mental illness;
  • Other conditions that, in the opinion of the investigator, may affect the results of the study;
  • Those who have used NMN or other anti-aging agents within six months.
  • Premenopausal woman
  • ALT, AST values are more than three times higher than the upper limit of the normal reference range

Key Trial Info

Start Date :

June 5 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 31 2027

Estimated Enrollment :

126 Patients enrolled

Trial Details

Trial ID

NCT06907329

Start Date

June 5 2025

End Date

March 31 2027

Last Update

July 8 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai, China